1. Scrip
  2. >>New Products

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

Tirzepatide Showed Superiority To Ozempic In Clinical Trials

 
• By Mandy Jackson

The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade. 

Top view of diabetes tester set with athlete's equipment; measuring tape, green dumbbell and fruit
Beyond diabetes, Lilly is developing tirzepatide for obesity, NASH and heart failure • Source: Shutterstock

Eli Lilly and Company has pledged revenue growth growing forward from selling greater volumes of its drugs rather than from raising the prices for its products. Winning US Food and Drug Administration approval on 13 May for diabetes drug Mounjaro (tirzepatide) is a major milestone in that strategy.

The FDA approved the glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) agonist to improve blood sugar control in adults with type...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.